ReiThera

Executive Summary

ReiThera is an Italian biotechnology company established in 2009, headquartered in Rome. The company operates a unique dual business model: as a Contract Development and Manufacturing Organization (CDMO) specializing in viral vectors for vaccines and gene therapies, and as a developer of its own therapeutic candidates targeting infectious diseases such as HIV and Marburg virus. The CDMO segment provides a stable revenue stream and leverages the company's expertise in GMP manufacturing, while the pipeline focuses on high-priority global health threats. Although still private, ReiThera's technology platform and strategic positioning in the viral vector space position it as a potentially attractive partner for larger pharma and a player in emerging pandemic preparedness efforts. Looking ahead, near-term value drivers include the progression of ReiThera's proprietary vaccine candidates. The company's HIV vaccine program is expected to yield initial Phase 1 clinical data in the coming quarters, while its Marburg virus vaccine candidate is advancing towards regulatory filings. Additionally, the CDMO business continues to secure new contracts, which could provide further validation and revenue growth. These catalysts, combined with the company's infrastructure and experienced management team, support a positive outlook, though the private nature of the company limits public visibility.

Upcoming Catalysts (preview)

• Q3 2026HIV Vaccine Phase 1 Data Readout50% success
• Q4 2026Marburg Vaccine IND Filing60% success
• Q3 2026New CDMO Partnership Announcement70% success